This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arhin, F. F.
Right arrow Articles by Moeck, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arhin, F. F.
Right arrow Articles by Moeck, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2008, p. 1597-1603, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01513-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing{triangledown}

Francis F. Arhin,1 Ingrid Sarmiento,1 Adam Belley,1 Geoffrey A. McKay,1 Deborah C. Draghi,2 Parveen Grover,2 Daniel F. Sahm,2 Thomas R. Parr Jr.,1 and Gregory Moeck1*

Targanta Therapeutics, Saint Laurent, Québec, Canada,1 Eurofins Medinet, Herndon, Virginia2

Received 22 November 2007/ Returned for modification 17 January 2008/ Accepted 18 February 2008

Oritavancin, a semisynthetic lipoglycopeptide with activity against gram-positive bacteria, has multiple mechanisms of action, including the inhibition of cell wall synthesis and the perturbation of the membrane potential. Approved guidelines for broth microdilution MIC assays with dalbavancin, another lipoglycopeptide, require inclusion of 0.002% polysorbate 80. To investigate the potential impact of polysorbate 80 on oritavancin susceptibility assays, we quantified the recovery of [14C]oritavancin from susceptibility assay plates with and without polysorbate 80 and examined the effect of the presence of polysorbate 80 on the oritavancin MICs for 301 clinical isolates from the genera Staphylococcus, Enterococcus, and Streptococcus. In the absence of polysorbate 80, [14C]oritavancin was rapidly lost from solution in susceptibility assay test plates: 9% of the input drug was recovered in broth at 1 h when [14C]oritavancin was tested at 1 µg/ml. Furthermore, proportionately greater losses were observed at lower oritavancin concentrations, suggesting saturable binding of oritavancin to surfaces. The inclusion of 0.002% polysorbate 80 or 2% lysed horse blood permitted the recovery of 80 to 100% [14C]oritavancin at 24 h for all drug concentrations tested. Concordantly, oritavancin MIC90s for streptococcal isolates, as determined in medium containing 2% lysed horse blood, were identical with and without polysorbate 80. In stark contrast, polysorbate 80 reduced the oritavancin MIC90s by 16- to 32-fold for clinical isolates of enterococci and staphylococci, which are typically cultured without blood. The results presented here provide evidence that the MIC data for oritavancin in the current literature significantly underestimate the potency of oritavancin in vitro. Moreover, the combination of data from MIC and [14C]oritavancin recovery studies supports the revision of the oritavancin broth microdilution method to include polysorbate 80 throughout the assay.

* Corresponding author. Mailing address: Department of Biology, Targanta Therapeutics 7170 Frederick Banting Street, Second Floor, Saint Laurent, Québec, Canada H4S 2A1. Phone: (514) 332-1008, ext 232. Fax: (514) 332-6033. E-mail: gmoeck{at}targanta.com

{triangledown} Published ahead of print on 25 February 2008.

Antimicrobial Agents and Chemotherapy, May 2008, p. 1597-1603, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01513-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Arhin, F. F., Draghi, D. C., Pillar, C. M., Parr, T. R. Jr., Moeck, G., Sahm, D. F. (2009). Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates. Antimicrob. Agents Chemother. 53: 4762-4771 [Abstract] [Full Text]  
  • McKay, G. A., Beaulieu, S., Sarmiento, I., Arhin, F. F., Parr, T. R. Jr., Moeck, G. (2009). Impact of Human Serum Albumin on Oritavancin In Vitro Activity against Enterococci. Antimicrob. Agents Chemother. 53: 2687-2689 [Abstract] [Full Text]  
  • McKay, G. A., Beaulieu, S., Arhin, F. F., Belley, A., Sarmiento, I., Parr, T. Jr, Moeck, G. (2009). Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63: 1191-1199 [Abstract] [Full Text]  
  • Nguyen, H. A., Denis, O., Vergison, A., Theunis, A., Tulkens, P. M., Struelens, M. J., Van Bambeke, F. (2009). Intracellular Activity of Antibiotics in a Model of Human THP-1 Macrophages Infected by a Staphylococcus aureus Small-Colony Variant Strain Isolated from a Cystic Fibrosis Patient: Pharmacodynamic Evaluation and Comparison with Isogenic Normal-Phenotype and Revertant Strains. Antimicrob. Agents Chemother. 53: 1434-1442 [Abstract] [Full Text]  
  • Belley, A., Neesham-Grenon, E., McKay, G., Arhin, F. F., Harris, R., Beveridge, T., Parr, T. R. Jr., Moeck, G. (2009). Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureus Cells In Vitro. Antimicrob. Agents Chemother. 53: 918-925 [Abstract] [Full Text]  
  • Belley, A., Harris, R., Beveridge, T., Parr, T. Jr., Moeck, G. (2009). Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus. Antimicrob. Agents Chemother. 53: 800-804 [Abstract] [Full Text]  
  • Baines, S. D., O'Connor, R., Saxton, K., Freeman, J., Wilcox, M. H. (2008). Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 62: 1078-1085 [Abstract] [Full Text]  
  • O'Connor, R., Baines, S. D., Freeman, J., Wilcox, M. H. (2008). In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J Antimicrob Chemother 62: 762-765 [Abstract] [Full Text]  
  • Belley, A., Neesham-Grenon, E., Arhin, F. F., McKay, G. A., Parr, T. R. Jr., Moeck, G. (2008). Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 3820-3822 [Abstract] [Full Text]  
  • Heine, H. S., Bassett, J., Miller, L., Bassett, A., Ivins, B. E., Lehoux, D., Arhin, F. F., Parr, T. R. Jr., Moeck, G. (2008). Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax. Antimicrob. Agents Chemother. 52: 3350-3357 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»